Tag Archives: LixiLan-L Phase III clinical trial

Sanofi: LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with or without metformin

LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ —  Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release